Compare CMMB & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMMB | SGLY |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | Israel | United States |
| Employees | 12 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 8.5M |
| IPO Year | 2023 | 2008 |
| Metric | CMMB | SGLY |
|---|---|---|
| Price | $2.16 | $0.87 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 106.6K | ★ 329.2K |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | 48.29 |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $1,813,193.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $55.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.35 | $0.18 |
| 52 Week High | $3.55 | $8.65 |
| Indicator | CMMB | SGLY |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 32.29 |
| Support Level | $1.47 | $0.34 |
| Resistance Level | $2.21 | $1.02 |
| Average True Range (ATR) | 0.21 | 0.17 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 8.97 | 3.43 |
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.